Log in to search using one of your social media accounts:

 

Comparison of two on-line risk calculators versus the detection of circulating prostate cells for the detection of high risk prostate cancer at first biopsy.

CONCLUSIONS: CPC detection was superior to the other models in predicting the presence of clinically significant prostate cancer at initial biopsy; potentially reduces the number of unnecessary biopsy while missing few significant cancers. Being a positive/negative test it avoids defining a cutoff value which may differ between populations. Multicenter studies to validate this method are warrented. PMID: 28613202 [PubMed - in process]
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research

Related Links:

Authors: Shah TT, To WKL, Ahmed HU Abstract INTRODUCTION: With level 1 evidence now available on the diagnostic accuracy of multiparametric magnetic resonance imaging (MRI) we must now utilise this data in developing an MRI-stratified diagnostic pathway for the early detection of prostate cancer. Areas covered: A literature review was conducted and identified seven randomised control trials (RCT's) assessing the diagnostic accuracy of such a pathway against the previously accepted systematic/random trans-rectal ultrasound guided (TRUS) biopsy pathway. The studies were heterogeneous in their design. Five studies ass...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Conclusions The present nomograms could help discriminate patients with PCa from healthy elder adults for standard treatment, and discriminate patients with HGPCa from vulnerable elder adults for modified treatment. External validation is expected.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
The purpose of this study was to estimate the impact of lesion visibility with TRUS on the prediction of CS-PCA with TRUS-MRI fusion biopsy.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Source Type: research
Conclusions An MPMRI-first strategy is effective and cost effective for the diagnosis of CS prostate cancer. These findings are sensitive to the test costs, sensitivity of MRI-targeted TRUSB, and long-term outcomes of men with cancer, which warrant more empirical research. This analysis can inform the development of clinical guidelines. Patient summary We found that, under certain assumptions, the use of multiparametric magnetic resonance imaging first and then up to two transrectal ultrasound-guided biopsy is better than the current clinical standard and is good value for money. The use of multiparametric magnetic resonan...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Patient selection for focal salvage remains difficult. Therefore, we developed and internally validated prediction models for biochemical failure (BF) and a composite endpoint (CE) following focal salvage high intensity focused ultrasound (HIFU) for radiorecurrent prostate cancer.
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Tags: Original article Source Type: research
Abstract ObjectivesTo evaluate the value of multiparametric magnetic resonance imaging (mpMRI) for the detection of significant prostate cancer (PCa) and to compare transperineal MRI/ultrasound‐fusion biopsy (fusPbx) to conventional transrectal systematic biopsy (sysPbx) in biopsy‐naïve patients. Patients and MethodsThis multicentre, prospective trial investigated biopsy‐naïve patients with suspicion of PCa undergoing transperineal fusPbx in combination with transrectal sysPbx (comPbx). The primary outcome was the detection of significant PCa defined as Gleason pattern four or five. Here, we present our ana...
Source: BJU International - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research
CONCLUSION: Our model, once externally validated, could allow for better selection of patients for focal salvage HIFU. PMID: 28927782 [PubMed - as supplied by publisher]
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
ConclusionsThe TCM algorithm is able to estimate tissue changes reliably during the HIFU procedure for prostate tissue ablation in real-time and can be used as a guide for HIFU dose delivery and tissue ablation control.
Source: Journal of Therapeutic Ultrasound - Category: Radiology Source Type: research
Edap (NSDQ:EDAP) said today it submitted a new FDA 510(k) application for its next-gen high-intensity focused ultrasound Focal One device designed to treat prostate cancer after withdrawing its previous application in July. The new application alllowed the France-based company to include a new set of clinical data, which it had decided to include following “advanced discussions” with the FDA earlier this year. “The new 510k review may be more efficient as the updates only pertain to the clinical section which includes new studies from active and academic Focal One centers in Europe. Our regulato...
Source: Mass Device - Category: Medical Devices Authors: Tags: 510(k) Food & Drug Administration (FDA) Regulatory/Compliance Ultrasound EDAP TMS SA Source Type: news
[Image from unsplash.com]From BrainScope’s pediatric traumatic brain injury assessment device to EOS Imaging releasing new surgery planning software, here are seven medtech stories we missed this week but thought were still worth a mention. 1. BrainScope to develop pediatric traumatic brain injury assessment device BrainScope announced in a Sept. 7 press release that it will immediately start creating a pediatric capability for its BrainScope One medical neurotechnology. The technology is an FDA-cleared handheld medical device that is designed to assess the full spectrum of traumatic brain injury. The company sa...
Source: Mass Device - Category: Medical Devices Authors: Tags: 510(k) Cardiac Assist Devices Cardiovascular Clinical Trials Diagnostics Food & Drug Administration (FDA) Imaging mHealth (Mobile Health) Neurological Regulatory/Compliance Research & Development Spinal AliveCor Bonesupport Bra Source Type: news
More News: Cancer | Cancer & Oncology | Prostate Cancer | Study | Ultrasound | Urology & Nephrology